V
DFTX

Veritable’s Definium Therapeutics DFTX Stock Holding History

Veritable’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,007
Closed -$10K – 858
2022
Q2 		$10K Hold
1,007
– – ﹤0.01% 902
2022
Q1 		$17K Hold
1,007
– – ﹤0.01% 905
2021
Q4 		$21K Hold
1,007
– – ﹤0.01% 907
2021
Q3 		$35K Hold
1,007
– – ﹤0.01% 875
2021
Q2 		$52K Buy
+1,007
New +$52.9K ﹤0.01% 860

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Veritable's DFTX Position: Q3 2022 in Review

Veritable sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 1,007 shares — an estimated $10K sold.

Veritable first reported a position in DFTX in Q2 2021 and held it in 5 quarters. The position peaked at $52K in Q2 2021. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Veritable reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Veritable sold 1,007 Definium Therapeutics shares in Q3 2022, an estimated $10K.
  • Veritable first reported a position in Definium Therapeutics in Q2 2021 and held it in 5 quarters.
  • Veritable's Definium Therapeutics position peaked at $52K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.